The Intercept @theintercept
The deal between Pfizer and Mylan led the former to withdraw its competitor from the market and partner with Mylan on Epipen, locking down a monopoly. Following the deal with Pfizer, Mylan drove the price above $600 within five years. https://t.co/vit5WFUDR5 — PolitiTweet.org